New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
08:31 EDTRADRite Aid reports January SSS up 0.3%
For the four weeks ended Jan. 26, 2013, same store sales increased 0.3% over the prior-year period. January front-end same store sales increased 4.2%, of which 2.4% was attributable to flu-related over-the-counter products. Pharmacy same store sales, which included an approximate 665 basis points negative impact from new generic introductions, decreased 1.4%. Prescription count at comparable stores increased 5% over the prior-year period, of which 3.4% was attributable to flu-related prescriptions and flu shots. Total drugstore sales for the four-week period decreased 0.5% to $1.914B compared to $1.923B for the same period last year. Prescription sales accounted for 68.9% of drugstore sales, and third party prescription sales represented 96.2 percent of pharmacy sales.
News For RAD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
11:10 EDTRADWalgreen slightly lower as pharmacy margin pressure continues
Shares of retail drugstore chain Walgreen (WAG) are down slightly after the company noted that it booked a non-cash loss of $866M in the fourth quarter and that it is continuing to endure pharmacy margin pressure. WHAT'S NEW: Walgreen reported Q4 adjusted EPS of 74c, which matched analysts' consensus. The company's Q4 revenue was $19.06B, which was only slightly higher than analysts $19.02B consensus. Customer traffic in Q4 comparable stores decreased 2.2% and basket size increased 3.5%, while total sales in comparable stores increased 5.4%. Walgreen said the quarter was negatively impacted by an $866M, or 90c per share, non-cash loss because it decided to exercise its option to buy the remaining stake in Alliance Boots early. In regards to its partnership with Alliance Boots, Walgreen said that it anticipates synergies of $650M in fiscal year 2015. Walgreen noted that it is moving forward with the implementation of its previously announced cost-reduction initiatives to achieve $1B in savings by the end of fiscal year 2017. The drugstore chain said that it will continue to work through pharmacy margin pressure. WHAT'S NOTABLE: During the company's conference call, Walgreen said that its generic drug inflation will be with the company "for awhile." The drugstore chain noted that inflation was the main headwind to pharmacy margins during the quarter. To combat this, Walgreen said it aims to focus on contracting strategy and will cut pharmacy costs by upping efficiencies. In terms of FY15, Walgreen said its tailwinds included an aging population, growth and chronic donations, new generics and consumerization of healthcare. The company says some headwinds during the quarter included reimbursement pressure, generic drug inflation, Medicare Part D Rate Step Down and the cautious consumer. The company anticipates closing the Alliance Boots partnership in calendar year 2015, as it works towards regulatory approvals and shareholder vote. Walgreen is looking to open an additional 1,000 stores to well-experience formats and foresees FY15 capital expenditures of $1.7B. First quarter interest expense is anticipated to be comparable to Q4 and Q1 tax rate of 30%. The company said that there won't be a material change in free cash flow in 2015. In August, Walgreen forecast fiscal year 2016 EPS of $4.25-$4.60 on revenue of $126B-$130B. At that time, Walgreen said the decision to buy the rest of Alliance Boots would not be an inversion transaction. The company previously said Timothy McLevish would succeed Wade Miquelon as executive vice president and Chief Financial Officer. PRICE ACTION: During morning trading, Walgreen fell 24c or 0.4%, to $59.36. Since its last earnings report, shares of the retail drugstore chain are down around 20%. OTHERS TO WATCH: Peers of Walgreen include Rite Aid (RAD), which is down 0.4% to $4.93, and CVS Health (CVS), which is relatively flat at $80.08.
September 25, 2014
06:02 EDTRADStocks with implied volatility movement; RAD WLT
Stocks with implied volatility movement; Rite Aid (RAD) 59, Walter Energy (WLT) 131 according to iVolatility.
September 24, 2014
11:04 EDTRADOptions with decreasing implied volatility
Subscribe for More Information
09:34 EDTRADActive equity options trading on open
Subscribe for More Information
September 19, 2014
16:24 EDTRADStocks rise after Fed keeps pledge for 'considerable time' before rate hike
Subscribe for More Information
September 18, 2014
16:00 EDTRADOptions Update; September 18, 2014
Subscribe for More Information
12:45 EDTRADOn The Fly: Midday Wrap
Subscribe for More Information
11:55 EDTRADRite Aid falls as drugstore chain trims FY15 view
Subscribe for More Information
10:27 EDTRADOptions with decreasing implied volatility
Subscribe for More Information
09:36 EDTRADActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL YHOO TWTR VVUS RAD PWE WFM TSLA PIR SHLD
09:15 EDTRADRite Aid remains 'optimistic' about FY16
Subscribe for More Information
09:02 EDTRADRite Aid sees current competitive enviornment to remain promotional in FY15
Subscribe for More Information
08:59 EDTRADOn The Fly: Pre-market Movers
Subscribe for More Information
07:04 EDTRADRite Aid cuts FY15 EPS view to 22c-33c, consensus 34c
Based upon current estimates for reimbursement rates and anticipated lower profitability from new generics and generic drugs that recently lost exclusivity, the company is expecting decreases in pharmacy margin in the second half of Fiscal 2015 as compared to its prior estimates and therefore is lowering its guidance for Adjusted EBITDA, net income and net income per diluted share. Previous EPS view was 30c-40c. Cuts FY15 high end of revenue view to $26B-$26.3B from $26B-$26.5B, consensus $26.29B. Now sees FY SSS up 3%-4% over FY14. Sees FY CapEx $525M. Sees adjusted EBITDA $1.2B-$1.275B.
07:02 EDTRADRite Aid reports Q2 EPS 13c, consensus 6c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use